Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey

Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey

Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey

Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey

Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey

Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey

Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey

Department of Urology, Bagcilar Training and Research Hospital, Istanbul, Turkey

C reactive protein, Neutrophils, Lymphocytes, Kidney, Cancer, Biopsy

This study aimed to investigate the predictive role of serum C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR) on renal mass biopsy outcomes. A total of 71 patients with suspected kidney masses who underwent renal mass biopsy procedure between January 2017 and January 2021 were retrospectively evaluated. Pathological results after the procedure were obtained and pre-procedural serum CRP and NLR levels were extracted from the patients’ data. The patients were grouped into benign and malignant pathology groups according to the histopa-thology results. The parameters were compared between the groups. Diagnostic role of the parameters in terms of sensitivity, specificity, and positive and negative predictive values was also determined. Additionally, Pearson correlation analysis, and univariate and multivariate cox proportional hazard regression analyses were also performed to investigate the above association with tumor diameter and pathology results, respectively. At the end of the analyses, a total of 60 patients had malignant pathology on histopathological investigations of the mass biopsy specimens, whereas the remaining 11 patients had a benign pathological diagnosis. Significantly higher CRP and NLR levels were detected in the malignant pathology group. The parameters positively correlated with the malignant mass diameter, as well. Serum CRP and NLR deter-mined the malignant masses before the biopsy with sensitivity and specificity of 76.6 and 81.8%, and 88.3 and 45.4%, respectively. Moreover, univariate and multivariate analyses showed that serum CRP level had a significant predictive value for malignant pathology (HR: 0.998, 95% CI: 0.940–0.967, P < 0.001 and HR: 0.951, 95% CI: 0.936–0.966, P < 0.001, respectively). In conclusion, serum CRP and NLR levels were significantly different in patients with malignant pathology after renal mass biopsy compared to the patients with benign pathology. Serum CRP level, in particular, diagnosed malignant pathologies with acceptable sensitivity and specificity values. Additionally, it had a substantial predictive role in determining the malign masses prior the biopsy. Therefore, pre-biopsy serum CRP and NLR levels may be used to predict the diagnostic outcomes of renal mass biopsy in clinical practice. Further studies with larger cohorts can prove our findings in the future.

1. Sahni VA, Silverman SG. Biopsy of renal masses: When and why. Cancer Imag. 2009;9(1):44–55. https://doi.org/10.1102/1470-7330.2009.0005
2. Gray RE, Harris GT. Renal cell carcinoma: Diagnosis and management. Am Fam Physician. 2019;99(3):179–84.
3. Campi R, Stewart GD, Staehler M, Dabestani S, Kuczyk MA, Shuch BM, et al. Novel liquid biomarkers and innovative imaging for kidney cancer diagnosis: What can be implemented in our practice today? A systematic review of the literature. Eur Urol Oncol. 2021;4(1):22–41. https://doi.org/10.1016/j.euo.2020.12.011
4. Herts BR, Baker ME. The current role of percutaneous biopsy in the evaluation of renal masses. Semin Urol Oncol. 1995;13(4):254–61.
5. Caoili EM, Davenport MS. Role of percutaneous needle biopsy for renal masses. Semin Intervent Radiol. 2014;31(11):20–6. https://doi.org/10.1055/s-0033-1363839
6. Hart PC, Rajab IM, Alebraheem M, Potempa LA. C-reactive protein and cancer-diagnostic and therapeutic insights. Front Immunol. 2020;11:595835. https://doi.org/10.3389/fimmu.2020.595835
7. Shrotriya S, Walsh D, Nowacki AS, Lorton C, Aktas A, Hullihen B, et al. Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. PLoS One. 2018;13(8):e0202555. https://doi.org/10.1371/journal.pone.0202555
8. Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int. 2007;27(9):793–806. https://doi.org/10.1007/s00296-007-0357-y
9. He X, Li JP, Liu XH, Zhang JP, Zeng QY, Chen H, et al. Prognostic value of C-reactive protein/albumin ratio in predicting overall survival of Chinese cervical cancer patients overall survival: Comparison among various inflammation based factors. J Cancer. 2018;9(10):1877–84. https://doi.org/10.7150/jca.23320
10. Shinohara S, Sugaya M, Onitsuka T, Machida K, Matsuo M, Tanaka F. Prognostic impact of postoperative C-reactive protein for non-small cell lung cancer following lobectomy. Anticancer Res. 2018;38(5):3193–8. https://doi.org/10.21873/anticanres.12584
11. Ko YJ, Kwon YM, Kim KH, Choi HC, Chun SH, Yoon HJ, et al. High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol Biomarkers Prev. 2012;21(11):2076–86. https://doi.org/10.1158/1055-9965.EPI-12-0611
12. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61(9):824–33. https://doi.org/10.1136/jech.2006.051292
13. Kuo C, Hsueh WT, Wu YH, Yang MW, Cheng YJ, Pao TH, et al. The role of pretreatment serum neutrophil-to-lymphocyte ratio in hypopharyngeal cancer treated with definitive chemoradiotherapy: A pilot study. Sci Rep. 20197;9(1):1618. https://doi.org/10.1038/s41598-018-38282-z
14. Faria SS, Fernandes PC, Jr., Silva MJ, Lima VC, Fontes W, Freitas-Junior R, et al. The neutrophil-to-lymphocyte ratio: A narrative review. Ecancermedicalscience. 2016;10:702. https://doi.org/10.3332/ecancer.2016.702
15. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–6. https://doi.org/10.1097/MCO.0b013e32832a7902
16. Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–12. https://doi.org/10.1158/1055-9965.EPI-14-0146
17. Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong C, Su F, Song E. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: A retrospective study. BMC Cancer. 2016;16:320. https://doi.org/10.1186/s12885-016-2352-8
18. Azab B, Camacho-Rivera M, Taioli E. Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects. PLoS One. 2014;9(11):e112361. https://doi.org/10.1371/journal.pone.0112361
19. Son SH, Park EY, Park HH, Kay CS, Jang HS. Pre-radiotherapy neutrophil-to-lymphocyte ratio as an independent prognostic factor in patients with locally advanced hepatocellular carcinoma treated with radiotherapy. Oncotarget. 2017;8(10):16964–71. https://doi.org/10.18632/oncotarget.15209